Top Articles Suggested by Talha Badar

Talha Badar, Hematology/Oncology Specialist at Mayo Clinic, shared some top articles on X:

1. “Correlates and consequences of clonal hematopoiesis expansion rate: a 16-year longitudinal study of 6976 women.

Key findings:

• Germline variants and telomere biology disorders influence clonal expansion.
• A small SF3B1 clone had a higher likelihood of expansion compared to TP53
• Nearly 65% DNMT3A.”

Read the post.

Title: Correlates and consequences of clonal hematopoiesis expansion rate: a 16-year longitudinal study of 6976 women

Authors: Yash Pershad, Md. Mesbah Uddin, Liying Xue, Jeffrey Haessler, Jason M. Collins, Taralynn M. Mack, Elena Glick, Veronica Glaser, Kun Zhao, Siddhartha Jaiswal, JoAnn E. Manson, Urvashi Pandey, Pinkal Desai, Pradeep Natarajan, Michael C. Honigberg, Charles Kooperberg, Eric A. Whitsel, Jacob O. Kitzman, Alexander G. Bick, Alexander P. Reiner

You can read the Full Article on Blood.

2. “Menin inhibition with revumenib for NPM1-mutated relapsed or refractory acute myeloid leukemia: the AUGMENT-101 study

Key findings:

• Response: CR/CRh 23.4%, DOR 4.7 mo
• AE: QTc prolongation 21.4%, Differentiation syndrome 13.1%

Subset analysis:

• Response inf in prior Ven exposed. Better in IDH1m.”

Read the post.

Title: Menin inhibition with revumenib for NPM1-mutated relapsed or refractory acute myeloid leukemia: the AUGMENT-101 study

Authors: Martha L. Arellano, Michael J. Thirman, John F. DiPersio, Maël Heiblig, Eytan M. Stein, Andre C. Schuh, Andrius Žučenka, Stephane de Botton, Carolyn S. Grove, Gabriel N. Mannis, Cristina Papayannidis, Alexander E. Perl, Ghayas C. Issa, Ibrahim Aldoss, Ashish Bajel, David S. Dickens, Michael W. M. Kühn, Ioannis Mantzaris, Emmanuel Raffoux, Elie Traer, Irina Amitai, Hartmut Döhner, Corinna Greco, Tibor Kovacsovics, Christine M. McMahon, Pau Montesinos, Arnaud Pigneux, Paul J. Shami, Richard M. Stone, Ofir Wolach, John G. Harpel, Yakov Chudnovsky, Li Yu, Rebecca G. Bagley, Angela R. Smith, James S. Blachly

You can read the Full Article on Blood.

3. “My editorial. Safe Platelet Count for Lumbar Puncture in Hematologic Malignancies

While 50 ×10⁹/L has long been considered the “safe” threshold for lumbar puncture, recent studies suggest lower counts (40 ×10⁹/L) may be acceptable in select patients with hem malignancies

The risk of spinal hematoma is very low, but delays in diagnostic or therapeutic LP due to transfusion can adversely impact outcomes.

Takeaway: Evidence supports a more flexible, individualized approach rather than a rigid platelet cutoff. Prospective trials are needed to establish definitive guidelines.”

Read the post.

Title: Safe platelet count for lumbar puncture: are we being overcautious?

Author: Talha Badar

You can read the Full Article on Haematologica.

4. “Upfront Immunotherapy Approaches in the Management of Adults with Acute Lymphoblastic Leukemia.

MDPI Cancers, open access, excellent contributions by Moazzam Shahzad, Muhammad Kashif Amin.”

Read the post.

Title: Upfront Immunotherapy Approaches in the Management of Adults with Acute Lymphoblastic Leukemia

Authors: Moazzam Shahzad, Muhammad Kashif Amin, Talha Badar

You can read the Full Article on Cancers.

5. “Happy to contribute to this multi-institutional study led by Caner Saygin on outcomes in TP53-mutated ALL.

Key findings:

• Overall survival (OS): Median OS < 2 years, regardless of B-cell or T-cell lineage.
• Treatment response: Blinatumomab (Blina) or inotuzumab ozogamicin (InO) yielded better responses than conventional chemotherapy, but the benefit was not durable.
• Cytogenetics: Frequently associated with hypodiploidy.
• Mutation status: No prognostic difference observed between monoallelic vs. biallelic TP53 mutations.”

Read the post.

Title: Clinical and molecular characterization of TP53-mutant acute lymphoblastic leukemia in adults

Authors: Ethan J. Harris, Diren Arda Karaoglu, Madina Sukhanova, Yasmin Abaza, Theodoros Karantanos, Ann-Kathrin Eisfeld, Clare Anderson, Chenyu Lin, Yenny A. Moreno Vanegas, Talha Badar, Alexander Coltoff, Todd C. Knepper, Neval Ozkaya, Hamed Rahmani Youshanlouei, Sinan Cetin, Anand A. Patel, Adam S. DuVall, Michael W. Drazer, Peng Wang, Melissa Tjota, Jeremy P. Segal, Girish Venkataraman, Sandeep Gurbuxani, Jason X. Cheng, Daniel A. Arber, Richard A. Larson, Olatoyosi Odenike, Jonathan Webster, Bijal Shah, Wendy Stock, Caner Saygin

You can read the Full Article on Blood Cancer Journal.

6. “Early View | Haematologica

Longer time from diagnosis to initiation of hypomethylating agents plus venetoclax for acute myeloid leukemia does not worsen survival: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND)
led by Samuel Yates, Rory Shallis.”

Read the post.

Title: Longer time from diagnosis to initiation of hypomethylating agents plus venetoclax for acute myeloid leukemia does not worsen survival: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND)

Authors: Samuel J. Yates, Julian J. Weiss, Abigail Sneider, Emily Geramita, Guru Subramanian Guru Murthy, Talha Badar, Annie Im, Chenyu Lin, Wei Cheng, Yasmin Abaza, Alok Swaroop, Eric S. Winer, Mark R. Litzow, Ehab L. Atallah, Anand Ashwin Patel, Rory M. Shallis

You can read the Full Article on Haematologica.

7. “Factors associated with survival after allogeneic transplantation for myeloid neoplasms harboring TP53 mutations.”

Read the post.

Title: Factors associated with survival after allogeneic transplantation for myeloid neoplasms harboring TP53 mutations

Authors: Anmol Baranwal, Kimberly J. Langer, Vedavyas Gannamani, Danielle Rud, Alia Cibich, Caner Saygin, Mariam Nawas, Talha Badar, Mohamed A. Kharfan-Dabaja, Ernesto Ayala, Vivek Roy, James M. Foran, Hemant S. Murthy, Madiha Iqbal, Jeanne Palmer, Lisa Z. Sproat, Saurabh Chhabra, Nandita Khera, Mehrdad Hefazi, Abhishek Mangaonkar, William Hogan, Mark Litzow, Hassan Alkhateeb, Ayalew Tefferi, Chung Hoow Kok, Guru Subramanian Guru Murthy, Anand Patel, Ashish Bajel, Devendra K. Hiwase, Mithun Vinod Shah

You can read the Full Article on Blood Advances.

8. “American Journal of Hematology | Blood Research Journal | Wiley Online Library.

PII trial of CPX-351 and Venetoclax, led by Dr. Tapan Kadia

CPX-351 dosed at daunorubicin 44 mg/m2 on days 1,3, and 5 and VEN 300 mg days 2–8) being chosen as the RP2D

1. RR AML (58% prior Ven, 30% prior alloHCT)
2. composite CR 39%.
3. 11 (73%) bridged to alloHCT.
4. 30 and 60 day TRM, 9% and 21%.
5. 2 yrs OS 49%.”

Read the post.

Title: A Phase 2 Trial of CPX-351 Combined With Venetoclax in Relapsed or Refractory Acute Myeloid Leukemia

Authors: Tapan M. Kadia, Wei-Ying Jen, Alex Bataller, Alexandre Bazinet, Gautam Borthakur, Elias Jabbour, Wei Qiao, Nicholas J. Short, Koichi Takahashi, Ghayas C. Issa, Courtney D. DiNardo, Guillermo Montalban-Bravo, Naveen Pemmaraju, Andrew Tran, Vanthana Bharathi, Sanam Loghavi, Amin M. Alousi, Uday Popat, Naval G. Daver, Farhad Ravandi, Hagop M. Kantarjian

You can read the Full Article on the American Journal of Hematology.

9. “Project EVOLVE: an international analysis of postimmunotherapy lineage switch, an emergent form of relapse in leukemia.

70 cases of B-cell ALL with lineage switch after immunotherapy (anti-CD19) to AML or mixed phenotypic leukemia.
Dismal outcome with median OS 4.9 months.”

Read the post.

Title: Project EVOLVE: an international analysis of postimmunotherapy lineage switch, an emergent form of relapse in leukemia

Authors: Sara K. Silbert, Alexander W. Rankin, Chloe N. Hoang, Alexandra Semchenkova, Regina M. Myers, Elena Zerkalenkova, Hao-Wei Wang, Alexandra E. Kovach, Constance M. Yuan, Dana Delgado Colon, Loïc Vasseur, Alex Bataller, Samuel John, Kaylyn Utley Lyons, Barbara Friedes, Anna Alonso-Saladrigues, Hisham Abdel-Azim, Estelle Balducci, Ahmed Assim Aljudi, Marie Balsat, D. Nathan Biery, Aghiad Chamdin, Bill H. Chang, Raymund S. Cuevo, Barbara De Moerloose, David S. Dickens, Ulrich Duffner, Nicolas Duployez, Firas El Chaer, Michelle Ann Elliott, Gabriele Escherich, Sneha Fernandes, Mandi R. Fitzjohn, Zhubin Gahvari, Stephan A. Grupp, Rui Rochelle He, Cynthia Harrison, Christopher B. Hergott, Emily M. Hsieh, Annette S. Kim, Dennis J. Kuo, Daniel P. Larson, Benjamin J. Lee, Thibaut Leguay, R. Coleman Lindsley, Abhishek A. Mangaonkar, Kerstin Mezger, Holly L. Pacenta, Jing Pan, Marlie Provost, Latika Puri, Sunil S. Raikar, Armando Martinez, Isabella Bristol, Kyle Murphy, Lauren Reiman, Michele Redell, Kelly Reed, Gabrielle Roth-Guepin, Jeremy Rubinstein, Süreyya Savaşan, Kristian Schafernak, Alexandra Stevens, Aimee Talleur, Naomi Torres Carapia, Jacques Vargaftig, Anant Vatsayan, Matthias Wölfl, Liping Zhao, Susana Rives, Vanessa A. Fabrizio, Koji Sasaki, Ibrahim Aldoss, Nicolas Boissel, Susan R. Rheingold, Kara L. Davis, Sara Ghorashian, Elad Jacoby, Alexander Popov, Adam J. Lamble, Nirali N. Shah

You can read the Full Article on Blood.

10. “Ruxolitinib combined with dexamethasone for adult patients with newly diagnosed hemophagocytic lymphohistiocytosis in China

The Ru-D regimen was well tolerated, resulting in OS rates of 85.7%, 67.9%, and 53.6% at 2 months, 6 months, and 2 years, respectively.”

Read the post.

Title: Ruxolitinib combined with dexamethasone for adult patients with newly diagnosed hemophagocytic lymphohistiocytosis in China

Authors: De Zhou, Xianbo Huang, Lixia Zhu, Xuelian Hu, Xiudi Yang, Mixue Xie, Xin Huang, Fang Yu, Juying Wei, Liya Ma, Jingjing Zhu, Shuqi Zhao, Wanzhuo Xie, Hongyan Tong, Jie Jin, Xiujin Ye

You can read the Full Article on Blood.

More posts featuring Talha Badar on OncoDaily.